A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

March 28, 2025

Study Completion Date

May 22, 2025

Conditions

Obesity

Interventions

DRUG

CagriSema (cagrilintide B and semaglutide I)

Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.

DRUG

CagriSema A

Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.

Trial Locations (1)

Celerion, Lincoln, Lincoln